Literature DB >> 34235656

Drug Susceptibility Screening Using In Vitro Models of Hypoxic Non-Replicating Persistent Mycobacteria.

Savannah E R Gibson1, James Harrison1, Jonathan A G Cox2.   

Abstract

Non-replicating persistence (NRP) is a functional adaptation that mycobacteria undergo in response to the stresses of the granuloma, facilitating antibiotic tolerance and long-term infection. These stresses, or NRP-inducing factors, include hypoxia, nutrient deprivation, and nitric oxide assault, which mycobacteria are well evolved to tolerate through a series of metabolic and physiological adaptations producing the NRP state. Most attempts to replicate these conditions in vitro have focused on only one of these factors at a time for ease and simplicity, but as a result, do not necessarily produce physiologically relevant phenotypes. Here, we provide the methods for two different in vitro NRP strategies that are useful for drug susceptibility testing and high-throughput screening.

Entities:  

Keywords:  Cholesterol minimal media; Drug discovery; High-throughput screening; Hypoxia; Latent tuberculosis infection; Non-replicating persistence; Nutrient deprivation; Susceptibility testing

Year:  2021        PMID: 34235656     DOI: 10.1007/978-1-0716-1460-0_10

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  2 in total

1.  Sequential adaptation in latent tuberculosis bacilli: observation by atomic force microscopy (AFM).

Authors:  Ali Akbar Velayati; Parissa Farnia; Mohammad Reza Masjedi; Gennady Konstantinovich Zhavnerko; Muayad Aghali Merza; Jalladein Ghanavi; Payam Tabarsi; Poopak Farnia; Nikolai Nikolaevich Poleschuyk; George Ignatyev
Journal:  Int J Clin Exp Med       Date:  2011-09-15

2.  Transcriptional Adaptation of Mycobacterium tuberculosis within Macrophages: Insights into the Phagosomal Environment.

Authors:  Dirk Schnappinger; Sabine Ehrt; Martin I Voskuil; Yang Liu; Joseph A Mangan; Irene M Monahan; Gregory Dolganov; Brad Efron; Philip D Butcher; Carl Nathan; Gary K Schoolnik
Journal:  J Exp Med       Date:  2003-09-01       Impact factor: 14.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.